Showing results (311-320 of 678) with videos related to

Sort By:
Pageof 68
Leukemia & Lymphoma|November 18, 2022
Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 studyJohn Kuruvilla, Philippe Armand, Mehdi Hamadani, et al.
American Journal of Hematology|February 21, 2019
Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentationJuan Pablo Alderuccio, Wei Zhao, Amrita Desai, et al.
Blood Cancer Journal|May 22, 2019
Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapseAnita Kumar, Fushen Sha, Ahmed Toure, et al.
The Lancet. Haematology|December 11, 2024
Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trialJuan Pablo Alderuccio, Alvaro J Alencar, Jonathan H Schatz, et al.
Blood|April 7, 2021
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study resultsRanjana H Advani, Alison J Moskowitz, Nancy L Bartlett, et al.
Blood Advances|March 19, 2024
Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score-matched analysisJulia Driessen, Fer de Wit, Alex F Herrera, et al.
Blood|July 28, 2018
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PETDavid J Straus, Sin-Ho Jung, Brandelyn Pitcher, et al.
British Journal of Haematology|January 21, 2010
High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imagingCraig H Moskowitz, Joachim Yahalom, Andrew D Zelenetz, et al.
Blood Advances|January 26, 2021
Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissueErel Joffe, Yan Leyfman, Esther Drill, et al.
Blood|February 2, 2018
A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCLCraig S Sauter, Matthew J Matasar, Heiko Schoder, et al.
Pageof 68